The judge in the trial called Guidant and Cook's agreement a "sham, " saying it violated a 1997 agreement that Boston Scientific and Cook signed with Angiotech Pharmaceuticals (nasdaq: ANPI - news - people ).
In 1997, Boston Scientific signed an agreement with Cook and Angiotech Pharmaceuticals (nasdaq: ANPI - news - people ), under which Cook and Boston Scientific were granted co-exclusive rights to use paclitaxel to coat coronary stents.
In 1997, Angiotech Pharmaceuticals (nasdaq: ANPI - news - people ) granted Cook and Boston Scientific (nyse: BSX - news - people ) co-exclusive rights to use the drug paclitaxel to coat coronary stents.